All In Biotech

Drug Trial Radar · NCT02725268

A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer

A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer

Last checked: Nov 19, 2026Latest source record: Nov 24, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 241 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

241

Actual

Start

Apr 1, 2016

Primary completion

Jul 2, 2019

Study completion Oct 30, 2020

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
Collaborators
European Network of Translational Research in Ovarian Cancer - EUTROC; European Network of Individualized Treatment in Endometrial Cancer - ENITEC
First posted
Mar 31, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to determine if sapanisertib in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.

Conditions

  • Endometrial Neoplasms

Interventions

  • PaclitaxelDrug

    Paclitaxel intravenous solution.

  • SapanisertibDrug

    Sapanisertib capsules.

  • MLN1117Drug

    MLN1117 capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: Up to approximately 30 months

Locations

78 sites in 10 countries. Site status is shown where the registry gives one.

  • University of Alabama Comprehensive Cancer Center

    Birmingham, Alabama

  • University of Arizona Cancer Center

    Phoenix, Arizona

  • Marin Cancer Care

    Greenbrae, California

  • University of California San Diego Medical Center

    La Jolla, California

  • University of California at San Francisco (PARENT)

    San Francisco, California

  • Stanford School of Medicine

    Stanford, California

  • H. Lee Moffitt Cancer Center and Research Institute, Inc

    Tampa, Florida

  • Florida Cancer Specialists

    West Palm Beach, Florida

  • Augusta University

    Augusta, Georgia

  • Franciscan St. Francis Health

    Indianapolis, Indiana

  • University of Kansas Medical Center Research Institute, Inc.

    Westwood, Kansas

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts

  • Washington University

    St Louis, Missouri

  • NYU Langone Medical Center Clinic

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Oklahoma University Health Sciences Center

    Oklahoma City, Oklahoma

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center Cancer Center at Magee-Womens Hospital

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • St George Hospital

    Kogarah, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Queensland, Australia

  • Monash Medical Centre Clayton

    Clayton, Victoria, Australia

  • Sunshine Hospital

    Footscray, Victoria, Australia

  • Cabrini Hospital Malvern

    Malvern, Victoria, Australia

  • Peter MacCallum Cancer Centre-East Melbourne

    Melbourne, Victoria, Australia

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • UZ Leuven

    Leuven, Belgium

  • Centre Hospitalier Universitaire de Liege Site Sart Tilman

    Liège, Belgium

  • GasthuisZusters Antwerpen Sint-Augustinus

    Wilrijk, Belgium

  • UZ Antwerpen

    Edegem, Antwerpen, Belgium

  • Tom Baker Cancer Centre

    Calgary, Alberta, Canada

  • Juravinski Cancer Clinic

    Hamilton, Ontario, Canada

  • LHSC - Victoria Hospital

    London, Ontario, Canada

  • Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada

  • University Health Network - Princess Margaret Cancer Centre

    Toronto, Ontario, Canada

  • CHUM Hopital Notre-Dame

    Montreal, Quebec, Canada

  • Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum

    Berlin, Germany

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.